- Home
- COLL vs QNST Comparison
COLL vs QNST Comparison
Compare COLL & QNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- QNST
- Stock Information
- Founded
- COLL 2002
- QNST 1999
- Country
- COLL United States
- QNST United States
- Employees
- COLL N/A
- QNST N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- QNST Business Services
- Sector
- COLL Health Care
- QNST Consumer Discretionary
- Exchange
- COLL Nasdaq
- QNST Nasdaq
- Market Cap
- COLL 958.8M
- QNST 923.2M
- IPO Year
- COLL 2015
- QNST 2010
- Fundamental
- Price
- COLL $38.32
- QNST $15.95
- Analyst Decision
- COLL Strong Buy
- QNST Buy
- Analyst Count
- COLL 4
- QNST 6
- Target Price
- COLL $44.25
- QNST $27.33
- AVG Volume (30 Days)
- COLL 427.8K
- QNST 665.8K
- Earning Date
- COLL 08-07-2025
- QNST 11-03-2025
- Dividend Yield
- COLL N/A
- QNST N/A
- EPS Growth
- COLL N/A
- QNST N/A
- EPS
- COLL 1.06
- QNST 0.08
- Revenue
- COLL $707,007,000.00
- QNST $1,093,711,000.00
- Revenue This Year
- COLL $22.23
- QNST $10.36
- Revenue Next Year
- COLL $2.78
- QNST $9.78
- P/E Ratio
- COLL $36.58
- QNST $197.25
- Revenue Growth
- COLL 22.61
- QNST 78.27
- 52 Week Low
- COLL $23.23
- QNST $14.27
- 52 Week High
- COLL $42.29
- QNST $26.27
- Technical
- Relative Strength Index (RSI)
- COLL 59.51
- QNST 55.46
- Support Level
- COLL $38.00
- QNST $15.07
- Resistance Level
- COLL $39.78
- QNST $15.76
- Average True Range (ATR)
- COLL 0.97
- QNST 0.44
- MACD
- COLL -0.18
- QNST 0.08
- Stochastic Oscillator
- COLL 38.72
- QNST 84.43
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia.